PADCEV®联合Keytruda®显著提高肌层浸润性膀胱癌患者生存率,无论顺铂适用性--对于符合条件的肌层浸润性膀胱癌患者,PADCEV联合Keytruda是首个且唯一在手术前后使用、无需含铂化疗即可改善无事件生存期和总生存期的方案--EV-304研究的积极数据,加上近期EV-303试验前所未有的结果,突显了该联合方案有潜力在膀胱癌更早阶段成为新的无铂标准治疗选择--EV-304 III期试验...
Source LinkPADCEV®联合Keytruda®显著提高肌层浸润性膀胱癌患者生存率,无论顺铂适用性--对于符合条件的肌层浸润性膀胱癌患者,PADCEV联合Keytruda是首个且唯一在手术前后使用、无需含铂化疗即可改善无事件生存期和总生存期的方案--EV-304研究的积极数据,加上近期EV-303试验前所未有的结果,突显了该联合方案有潜力在膀胱癌更早阶段成为新的无铂标准治疗选择--EV-304 III期试验...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.